Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Acyclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.91 |
| ▸ | BLM | P54132 | 2/20 | 0.91 |
| ▸ | HBB | P68871 | 2/20 | 0.91 |
| ▸ | USP2 | O75604 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 1/20 | 0.91 |
| ▸ | EDNRA | P25101 | 1/20 | 0.91 |
| ▸ | HTR2A | P28223 | 1/20 | 0.91 |
| ▸ | RECQL | P46063 | 1/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.91 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.81 |
| ▸ | POLG | P54098 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | VCP | P55072 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acyclovir SCHEMBL145606 | 1.00 | PNP (0.91) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL145614 | 1.00 | PNP (0.91) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL23440044 | 1.00 | PNP (0.91) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL11310314 | 0.99 | PNP (0.88) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL28326009 | 0.99 | PNP (0.88) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL11310318 | 0.99 | PNP (0.88) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL571377 | 0.95 | PNP (0.86) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL6917017 | 0.95 | PNP (0.86) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3664893 | 0.95 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3175 | 0.95 | PNP (1.00) | PNPBLMHBBUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | claimed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-6015573-A | TREATMENT OF RESISTANT HERPES VIRUS WITH NUCLEOSIDE PHOSPHATE ESTERS | RESOLUTION PERFORMANCE PRODUCTS LLC | 2000-01-18 | — | — | US | claimed |
| EP-0831794-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1998-11-04 | — | — | EP | claimed |
| EP-0831794-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0746319-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1996040088-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0746319-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1996-12-11 | — | — | EP | claimed |
| US-5580571-A | ACYCLOIR MONO OR DIPHOSPHATE; TOPICAL USE IN HERPES VIRUSINFECTIONS | HOSTETLER KARL Y (US) | 1996-12-03 | — | — | US | claimed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | claimed |
| CN-108601746-B | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery | 加利福尼亚大学董事会 | 2024-09-13 | — | — | CN | disclosed |
| US-11857566-B2 | Sulfonated polystyrene derivative for use in the treatment and/or prophylaxis of cat flu | UNIWERSYTET JAGIELLONSKI (PL) | 2024-01-02 | — | — | US | disclosed |
| EP-3890754-B1 | A SULFONATED POLYSTYRENE DERIVATIVE FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF CAT FLU | UNIV JAGIELLONSKI (PL) | 2022-11-30 | — | — | EP | disclosed |
| US-20220175824-A1 | A SULFONATED POLYSTYRENE DERIVATIVE FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF CAT FLU | UNIWERSYTET JAGIELLONSKI (PL) | 2022-06-09 | — | — | US | disclosed |
| EP-3890754-A1 | A SULFONATED POLYSTYRENE DERIVATIVE FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF CAT FLU | UNIWERSYTET JAGIELLONSKI (PL) | 2021-10-13 | — | — | EP | disclosed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0531452-A4 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | — | 1993-06-09 | — | — | EP | disclosed |
| EP-0531452-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | NeXstar Pharmaceuticals, Inc. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0478292-A1 | Heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-01 | — | — | EP | disclosed |
| WO-1991018914-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | VICAL, INC. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857566-B2 | Sulfonated polystyrene derivative for use in the treatment and/or prophylaxis of cat flu | CAT, CALU, PIGO | PNP 3832/4885BLM 3168/4885HBB 3833/4885 |
| US-20220175824-A1 | A SULFONATED POLYSTYRENE DERIVATIVE FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF CAT FLU | CAT, PIGO, CALU | PNP 3526/4885BLM 3028/4885HBB 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.